IRLAB A — IRLAB Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK165.12m
- SEK155.10m
- SEK57.46m
Brief: Irlab CEO To Step Down During Q1 2027
Brief: Irlab Therapeutics Q2 Operating Loss SEK 16.7 Mln
Brief: IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln
Brief: IRLAB Q1 Operating Result Swings To Profit Of SEK 10.7 Mln
Brief: IRLAB Resolves On Rights Issue, Obtains Extended Loan Financing
Brief: Study Progress Triggers $3 Mln Payment For IRLAB
Sweden's IRLAB Q4 net sales fall sharply yr/yr
Brief: IRLAB Q4 Sales SEK 14.7 Million
Brief: IRLAB Enters Collaboration Agreement With Danish Biotech Co Biomia
Brief: IRLAB Therapeutics Gets Approvals For Phase Ib Study Of IRL757
Brief: Irlab Gets Acceptance For Two Abstracts At 20Th International Conference On Alzheimer’s, Parkinson’s Diseases
Brief: IRLAB Q3 Sales SEK 18.8 Million
Brief: IRLAB Gets $4 Mln Payment From MSRD For IRL757 Study
Brief: Irlab Is Granted Patent Strengthening Market Exclusivity Of Drug Candidate Mesdopetam In China
Brief: IRLAB Q2 Sales SEK 19.5 Million
Brief: IRLAB Appoints Roy Jonebrant As Interim CFO
Brief: Irlab CFO Viktor Siewertz Leaves The Company
Brief: IRLAB Raises About SEK 115.7 Mln On Rights Issue
Brief: Irlab Board Resolves On SEK 136 Mln Rights Issue